Soleno Therapeutics (SLNO) Common Equity (2016 - 2019)
Historic Common Equity for Soleno Therapeutics (SLNO) over the last 7 years, with Q3 2019 value amounting to $14.9 million.
- Soleno Therapeutics' Common Equity rose 478.7% to $14.9 million in Q3 2019 from the same period last year, while for Sep 2019 it was $14.9 million, marking a year-over-year increase of 478.7%. This contributed to the annual value of $30.4 million for FY2018, which is 1340.94% up from last year.
- According to the latest figures from Q3 2019, Soleno Therapeutics' Common Equity is $14.9 million, which was up 478.7% from $13.8 million recorded in Q2 2019.
- In the past 5 years, Soleno Therapeutics' Common Equity ranged from a high of $30.4 million in Q4 2018 and a low of -$11.3 million during Q1 2015
- Over the past 5 years, Soleno Therapeutics' median Common Equity value was $14.2 million (recorded in 2018), while the average stood at $12.8 million.
- Its Common Equity has fluctuated over the past 5 years, first soared by 92252.87% in 2017, then tumbled by 4065.87% in 2018.
- Over the past 5 years, Soleno Therapeutics' Common Equity (Quarter) stood at $3.2 million in 2015, then increased by 6.56% to $3.4 million in 2016, then skyrocketed by 680.65% to $26.8 million in 2017, then rose by 13.41% to $30.4 million in 2018, then plummeted by 51.06% to $14.9 million in 2019.
- Its Common Equity was $14.9 million in Q3 2019, compared to $13.8 million in Q2 2019 and $23.6 million in Q1 2019.